FXR agonists were demonstrated to inhibit the development of NASH in rodent models of HFD-induced NASH, where they also promoted the resolution of steatohepatitis and fibrosis [98]. This evidence concerns the gene NR1H4 and metabolic dysfunction-associated steatohepatitis.